These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 33154114)
1. 'A very, very bad look' for remdesivir. Cohen J; Kupferschmidt K Science; 2020 Nov; 370(6517):642-643. PubMed ID: 33154114 [No Abstract] [Full Text] [Related]
3. FDA Approval of Remdesivir - A Step in the Right Direction. Rubin D; Chan-Tack K; Farley J; Sherwat A N Engl J Med; 2020 Dec; 383(27):2598-2600. PubMed ID: 33264539 [No Abstract] [Full Text] [Related]
4. Commentary: "Emergency Use Authorization for Remdesivir: A Pediatric Perspective". Noel GJ; Connor E Pediatr Infect Dis J; 2020 Sep; 39(9):e234. PubMed ID: 32639464 [No Abstract] [Full Text] [Related]
5. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. Chatterjee S Drug Res (Stuttg); 2021 Mar; 71(3):138-148. PubMed ID: 33124007 [TBL] [Abstract][Full Text] [Related]
6. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. Chua KP; Conti RM JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187 [No Abstract] [Full Text] [Related]
7. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19. Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898 [No Abstract] [Full Text] [Related]
8. Remdesivir for COVID-19 in Europe: will it provide value for money? Dal-Ré R; Banzi R; Georgin-Lavialle S; Porcher R; Sofat R; Zeitlinger M; Rosendaal FR Lancet Respir Med; 2021 Feb; 9(2):127-128. PubMed ID: 33341157 [No Abstract] [Full Text] [Related]
9. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. Ison MG; Wolfe C; Boucher HW JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438 [No Abstract] [Full Text] [Related]
10. The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access. Goldstein RH; Walensky RP JAMA; 2020 Dec; 324(21):2151-2152. PubMed ID: 33175110 [No Abstract] [Full Text] [Related]
11. An EUA for baricitinib (Olumiant) for COVID-19. Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175 [No Abstract] [Full Text] [Related]
12. Leaks of Clinical Trial Data and Research Integrity. Rajkumar SV; Sampathkumar P Mayo Clin Proc; 2020 Jul; 95(7):1318-1319. PubMed ID: 32622439 [No Abstract] [Full Text] [Related]
13. A Potential Antiviral Treatment for COVID-19: Remdesivir. O'Malley PA Clin Nurse Spec; 2020; 34(6):257-260. PubMed ID: 33009111 [No Abstract] [Full Text] [Related]
14. Remdesivir: a pendulum in a pandemic. Schwartz IS; Heil EL; McCreary EK BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523 [No Abstract] [Full Text] [Related]
15. Remdesivir (Veklury) for COVID-19. Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491 [No Abstract] [Full Text] [Related]
16. Assessing the evidence on remdesivir. Trøseid M; Hites M; Barratt-Due A; Ader F; Yazdanpanah Y Lancet Infect Dis; 2021 Dec; 21(12):1630-1631. PubMed ID: 34838222 [No Abstract] [Full Text] [Related]
20. Remdesivir in The Treatment of COVID-19. Rosenberg K Am J Nurs; 2021 Jan; 121(1):55. PubMed ID: 33350698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]